Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

被引：4
|
作者：
William, Basem M. [1 ]
Huang, Ying [1 ]
Johnson, Amy [2 ]
Brammer, Jonathan E. [3 ]
Reneau, John C. [2 ]
Maakaron, Joseph [2 ]
Larbi, Ruth [2 ]
Grantier, Cara [2 ]
Hoffman, Corinne [2 ]
Ayyappan, Sabarish [3 ]
Baiocchi, Robert A. [2 ]
Epperla, Narendranath [2 ]
Christian, Beth A. [1 ]
Alinari, Lapo [2 ]
Maddocks, Kami J. [2 ]
Chung, Catherine [2 ]
机构：
[1] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[2] Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp & Richard J Solove Res I, Div Hematol, Columbus, OH 43210 USA
[3] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH 43210 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-123801
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2853
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma
    Foss, Francine
    Advani, Ranjana
    Duvic, Madeleine
    Hymes, Kenneth B.
    Intragumtornchai, Tanin
    Lekhakula, Arnuparp
    Shpilberg, Ofer
    Lerner, Adam
    Belt, Robert J.
    Jacobsen, Eric D.
    Laurent, Guy
    Ben-Yehuda, Dina
    Beylot-Barry, Marie
    Hillen, Uwe
    Knoblauch, Poul
    Bhat, Gajanan
    Chawla, Shanta
    Allen, Lee F.
    Pohlman, Brad
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (06) : 811 - 819
  • [32] Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis
    Duvic, Madeleine
    Tetzlaff, Michael T.
    Gangar, Pamela
    Clos, Audra L.
    Sui, Dawen
    Talpur, Rakhshandra
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3759 - +
  • [33] Preclinical analysis of an autologous CD4-targeted chimeric antigen receptor T-cell (CAR-T) immunotherapy for relapsed or refractory peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL).
    Zeng, Eric
    Zhan, Tailan
    Wu, Yang
    Chen, Meili
    Wang, Junzheng
    Zhang, Yun
    Tu, Xiaojie
    Yang, Shuai
    Zhang, Wang
    Nesheiwat, Tonia
    Liang, Frank
    Tadagavadi, Raghu
    Chai, Kathy
    Geng, Dong
    Wu, Shu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Prediction of Clinical Response By Phased Variants in Circulating Tumor DNA (ctDNA) in the VALENTINE-PTCL01 Trial of Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)
    Mehta-Shah, Neha
    Horwitz, Steven
    Zinzani, Pier Luigi
    Barta, Stefan K.
    Yamagishi, Makoto
    Kurtz, David M.
    Takayama, Gensuke
    Hizukuri, Yoshiyuki
    Feng, Weiguo
    Chang, Ken C. N.
    Moriyama, Takaya
    Nakajima, Keiko
    Inoue, Ai
    Bachy, Emmanuel
    BLOOD, 2024, 144 : 4342 - 4343
  • [35] Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial
    O'Connor, Owen A.
    Masszi, Tamas
    Savage, Kerry J.
    Pinter-Brown, Lauren C.
    Foss, Francine M.
    Popplewell, Leslie
    Cashen, Amanda F.
    Doorduijn, Jeanette
    Chawla, Shanta
    Knoblauch, Poul
    Zinzani, Pier Luigi
    Brown, Peter
    Hess, Georg
    Van Hoof, Achiel
    Horwitz, Steven M.
    Shustov, Andrei R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] First interim analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
    Zhang, Huilai
    Cheng, Ying
    Yang, Haiyan
    Zhang, Liling
    Zou, Liqun
    Guo, Ye
    Cao, Junning
    Huang, Huiqiang
    Wang, Zhao
    Huang, Sha
    Liang, Zhiyu
    Lyu, Jiaoyan
    Fang, Yiqian
    Cohen, Aileen
    Zhou, Keshu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Case Match Control Analysis of Propel Reveals Survival Advantage for Patients with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) Treated with Pralatrexate
    O'Connor, Owen A.
    Marchi, Enrica
    Volinn, Weining
    Kim, Won Seog
    BLOOD, 2016, 128 (22)
  • [38] Valemetostat for Patients With R/R Peripheral T- Cell Lymphomas (PTCLs): A Phase 2 VALENTINE-PTCL01 Trial
    Horwitz, Steven
    Izutsu, Koji
    Mehta-Shah, Neha
    Cordoba, Raul
    Barta, Stefan
    Bachy, Emmanuel
    Gritti, Giuseppe
    Jacobsen, Eric
    Kusumoto, Shigeru
    Guillermin, Yann
    Prica, Anca
    Yoon, Dok Hyun
    Domenech, Eva Domingo
    Wang, Jie
    Kim, Jin Seok
    Cwynarski, Kate
    van der Poel, Marjolein
    Inoue, Ai
    Jin, Jin
    Wu, Sutan
    Nakajima, Keiko
    Zinzani, Pier Luigi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S524 - S525
  • [39] Two Phase I and Pharmacokinetic Studies of Darinaparsin (Organic Arsenic Compound) in Japanese and Korean Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)
    Kim, Won-Seog
    Ogura, Michinori
    Uchida, Toshiki
    Uike, Naokuni
    Abe, Yasunobu
    Ishizawa, Kenichi
    Okitsu, Yoko
    Tobinai, Kensei
    Nagahama, Fumiko
    Sonehara, Yusuke
    Nagai, Hirokazu
    BLOOD, 2015, 126 (23)
  • [40] Polatuzumab vedotin (Pola) plus rituximab (R) plus lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.
    Diefenbach, Catherine S. Magid
    Abrisqueta, Pau
    Gonzalez-Barca, Eva
    Panizo, Carlos
    Perez, Jose Maria Arguinano
    Miall, Fiona
    Bastos-Oreiro, Mariana
    Lopez-Guillermo, Armando
    Banerjee, Lalita
    McMillan, Andrew
    Hirata, Jamie
    Musick, Lisa
    Saha, Sourish
    Croft, Brandon
    Seymour, Erlene Kuizon
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345